Amgen announced it will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Key executives Jay Bradner and Thomas Dittrich will discuss the company's research, development, artificial intelligence initiatives, and financial outlook. The presentation will be webcast live and archived for 90 days, providing investors and the public access to Amgen's latest business developments. This event highlights Amgen's ongoing innovation in biotechnology and its commitment to advancing treatments for serious diseases.
Novartis' failed cholesterol drug trial for pelacarsen caused a sharp 14% drop in its stock and dragged down the entire Lp(a) drug class, hitting Amgen hardest with a 10% decline despite Amgen's positive Phase 3 lung cancer trial results announced th...
Jim Cramer recommended buying Johnson & Johnson (JNJ) shares during a recent dip, citing upcoming data from the Psych Congress conference and strong sales growth. Despite a 2.33% drop in the session, JNJ has outperformed the market with a 53.76% gain...
Investment firm BMO Capital downgraded Amgen's stock from "Outperform" to "Market Perform" following a major clinical trial failure by Novartis for a similar cholesterol drug. Novartis' drug pelacarsen failed in a late-stage Phase III trial, casting ...
Amgen's Phase 3 DeLLphi-305 study demonstrated that IMDELLTRA (tarlatamab-dlle) combined with AstraZeneca's durvalumab significantly improves overall survival, progression-free survival, and response rates compared to durvalumab alone in patients wit...
Novartis announced that its drug pelacarsen, designed to lower the harmful cholesterol Lp(a), failed to significantly reduce cardiovascular events in a late-stage trial. This setback raises doubts about the effectiveness of targeting Lp(a) to prevent...
